The nonnucleoside reverse transcription inhibitor MIV-160 delivered from an intravaginal ring, but not from a carrageenan gel, protects against simian/human immunodeficiency virus-RT infection

AIDS Research and Human Retroviruses

Volumn 28, Issue 11, 2012, Pages 1467-1475

  Aravantinou, Meropi ^a   Singer, Rachel ^a   Derby, Nina ^a   Calenda, Giulia ^a   Mawson, Paul ^a   Abraham, Ciby J ^a   Menon, Radhika ^a   Seidor, Samantha ^a   Goldman, Daniel ^a   Kenney, Jessica ^a   Villegas, Guillermo ^a   Gettie, Agegnehu ^b   Blanchard, James ^c   Lifson, Jeffrey D ^d   Piatak, Michael ^d   Fernández Romero, José A ^a   Zydowsky, Thomas M ^a   Teleshova, Natalia ^a   Robbiani, Melissa ^a  

^a POPULATION COUNCIL   (United States)

^b ROCKEFELLER UNIVERSITY   (United States)

^c TULANE NATIONAL PRIMATE RESEARCH CENTER   (United States)

^d SAIC FREDERICK INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARRAGEENAN; MIV 160; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; PLACEBO; UNCLASSIFIED DRUG;

ANIMAL TISSUE; ANTIVIRAL ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG RELEASE; EXPLANT; FEMALE; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IN VITRO STUDY; IN VIVO STUDY; MACACA; NONHUMAN; PRIORITY JOURNAL; SIMIAN ACQUIRED IMMUNODEFICIENCY SYNDROME; VAGINA RING; VIREMIA;

EID: 84868521229     PISSN: 08892229     EISSN: 19318405     Source Type: Journal    
DOI: 10.1089/aid.2012.0080     Document Type: Article

References (58)

1. Celum C and Baeten JM: Tenofovir-based pre-exposure prophylaxis for HIV prevention: Evolving evidence. Curr Opin Infect Dis 2012;25;51-5 7.
2. Abdool Karim Q, et al.: Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women. Science 2010;329:1168-1174.
3. Grant RM, et al.: Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N Engl J Med 2010;363:2587-2599.
4. Skoler-Karpoff S, et al.: Efficacy of Carraguard for prevention of HIV infection in women in South Africa: A randomised, double-blind, placebo-controlled trial. Lancet 2008;372:1977-1987.
5. Fernández-Romero JA, etal.: Carrageenan/MIV-150 (PC-815), a combination microbicide. Sex Transm Dis 2007;34:9-14.
6. Fernandez-Romero JA, et al.: Zinc acetate/carrageenan gels exhibit potent activity in vivo against high-dose herpes simplex virus 2 vaginal and rectal challenge. Antimicrob Agents Chemother 2012;56:358-368.
7. Buck CB, et al.: Carrageenan is a potent inhibitor of papil-lomavirus infection. PLoS Pathog 2006;2:e69.
8. Roberts JN, et al.: Genital transmission of HPV in a mouse model is potentiated by nonoxynol-9 and inhibited by car-rageenan. Nat Med 2007;13:857-861.
9. Marais D, et al.: The effectiveness of Carraguard, a vaginal microbicide, in protecting women against high-risk human papillomavirus infection. Antiviral Ther 2011;16:1219-1226.
10. Roberts JN, et al.: Effect of Pap smear collection and carra-geenan on cervicovaginal human papillomavirus-16 infection in a rhesus macaque model. J Natl Cancer Inst 2011;103:737-743.
11. Kerns J and Darney P: Vaginal ring contraception. Contraception 2011;83:107-115.
12. Malcolm RK, et al.: Advances in microbicide vaginal rings. Antiviral Res 2010;88(Suppl 1):S30-3 9.
13. Romano J, et al.: Safety and availability of dapivirine (TMC120) delivered from an intravaginal ring. AIDS Res Hum Retroviruses 2009;25:483-488.
14. Barentsen R, et al.: Continuous low dose estradiol released from a vaginal ring versus estriol vaginal cream for urogenital atrophy. Eur J Obstet Gynecol Reprod Biol 1997; 71:73-80.
15. Kenney J, et al.: An antiretroviral/zinc combination gel provides 24 hours of complete protection against vaginal SHIV infection in macaques. PLoS One 2011;6:e15835.
16. Singer R, et al.: A non-nucleoside reverse transcriptase inhibitor MIV-150 intravaginal ring reduces SHIV transmission in macaques. Science Translational Medicine 2012 [In Press].
17. Singer R, et al.: The nonnucleoside reverse transcriptase inhibitor MIV-150 in carrageenan gel prevents rectal transmission of simian/human immunodeficiency virus infection in macaques. J Virol 2011;85:5504-5512.
18. Turville SG, et al.: Efficacy of Carraguard-based microbicides in vivo despite variable in vitro activity. PLoS One 2008; 3:e3162.
19. D'Cruz OJ and Uckun FM: Dawn of non-nucleoside inhibitor-based anti-HIV microbicides. J Antimicrob Chemother 2006;57:411-423.
20. Sahlberg C and Zhou XX: Development of non-nucleoside reverse transcriptase inhibitors for anti-HIV therapy. AntiInfect Agents Med Chem 2008;7:101-117.
21. Selhorst P, et al.: Human immunodeficiency virus type 1 resistance or cross-resistance to nonnucleoside reverse transcriptase inhibitors currently under development as microbicides. Antimicrob Agents Chemother 2011;55:1403-1413.
22. Animal Welfare Act and Regulation of 2001: Code of Federal Regulations, t., chapter 1, subchapter A: Animals and Animal Products. U.S. Department of Agriculture, Beltsville, MD.
23. Committee on Care and Use of Laboratory Animals of the Institute of Laboratory Animal Resources Guide for the Care and Use of Laboratory Animals: Vol. Publication no. 85-23 1-83. U.S. Department of Health and Human Services, National Institutes of Health, Bethesda, MD, 1985.
24. Greenhead P, et al.: Parameters of human immunodeficiency virus infection of human cervical tissue and inhibition by vaginal virucides. J Virol 2000;74:5577-5586.
25. Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-delta delta C(T)) method. Methods 2001;25:402-408.
26. Frank I, et al.: A fusion inhibitor prevents spread of immunodeficiency viruses, but not activation of virus-specific T cells, by dendritic cells. J Virol 2008;82:5329-5339.
27. Tang L, et al.: Evaluation and selection of bio-relevant dissolution media for a poorly water-soluble new chemical entity. Pharm Dev Technol 6, 531-540 (2001).
28. Begay O, et al.: Identification of personal lubricants that can cause rectal epithelial cell damage and enhance HIV type 1 replication in vitro. AIDS Res Hum Retroviruses 2011;27:1019-1024.
29. Hild-Petito S, et al.: Effects of two progestin-only contraceptives, Depo-Provera and Norplant-II, on the vaginal epithelium of rhesus monkeys. AIDS Res Hum Retroviruses 1998;14(Suppl 1):S125-S130.
30. Crostarosa F, et al.: A macaque model to study vaginal HSV-2/immunodeficiency virus co-infection and the impact of HSV-2 on microbicide efficacy. PLoS One 2009;4:e8060.
31. Chien YW and Lambert HJ: Controlled drug release from polymeric delivery devices. II. Differentiation between partition-controlled and matrix-controlled drug release mechanisms. J Pharm Sci 1974;63:515-519.
32. Woolfson AD, et al.: Intravaginal ring delivery of the reverse transcriptase inhibitor TMC 120 as an HIV microbicide. Int J Pharm 2006;325:82-89.
33. Malcolm RK, et al.: Sustained release of the CCR5 inhibitors CMPD167 and maraviroc from vaginal rings in rhesus macaques. Antimicrobial Agents Chemother 2012;56:2251-2258.
34. Wang L, et al.: Rectal microbicides: Clinically relevant approach to the design of rectal specific placebo formulations. AIDS Res Ther 2011;8:12.
35. Rohan LC and Sassi AB: Vaginal drug delivery systems for HIV prevention. Aaps J 2009;11:78-87.
36. Hladik F and Doncel GF: Preventing mucosal HIV transmission with topical microbicides: Challenges and opportunities. Antiviral Res 2010;88(Suppl 1):S3-9.
37. Cummins JE Jr, et al.: Preclinical testing of candidate topical microbicides for anti-human immunodeficiency virus type 1 activity and tissue toxicity in a human cervical explant culture. Antimicrob Agents Chemother 2007;51:1770-1779.
38. Beer BE, et al.: In vitro preclinical testing of nonoxynol-9 as potential anti-human immunodeficiency virus microbicide: A retrospective analysis of results from five laboratories. Antimicrob Agents Chemother 2006;50:713-723.
39. Kreiss J, et al.: Efficacy of nonoxynol 9 contraceptive sponge use in preventing heterosexual acquisition of HIV in Nairobi prostitutes. JAMA 1992;268:477-482.
40. Roddy RE, et al.: A controlled trial of nonoxynol 9 film to reduce male-to-female transmission of sexually transmitted diseases. N Engl J Med 1998;339:504-510.
41. Van Damme L, et al.: Effectiveness of COL-1492, a nonoxynol-9 vaginal gel, on HIV-1 transmission in female sex workers: A randomised controlled trial. Lancet 2002;360:971-907.
42. McGowan I: Microbicides for HIV prevention: Reality or hope? Curr Opin Infect Dis 2010;23:26-31.
43. Lackman-Smith C, et al.: Development of a comprehensive human immunodeficiency virus type 1 screening algorithm for discovery and preclinical testing of topical microbicides. Antimicrob Agents Chemother 2008;52:1768-1781.
44. Morrow KM and Hendrix C: Clinical evaluation of micro-bicide formulations. Antiviral Res 2010;88(Suppl 1):S40-4 6.
45. Parikh UM, et al.: Complete protection from repeated vaginal simian-human immunodeficiency virus exposures in macaques by a topical gel containing tenofovir alone or with emtricitabine. J Virol 2009;83:10358-10365.
46. Dobard C, et al.: Durable protection from vaginal simian-human immunodeficiency virus infection in macaques by tenofovir gel and its relationship to drug levels in tissue. J Virol 2012;86:718-725.
47. Cranage M, et al.: Prevention of SIV rectal transmission and priming of T cell responses in macaques after local pre-exposure application of tenofovir gel. PLoS Med 2008;5:e157; discussion e157.
48. Rohan LC, et al.: In vitro and ex vivo testing of tenofovir shows it is effective as an HIV-1 microbicide. PLoS One 2010;5:e9310.
49. Johnson TJ, et al.: Segmented polyurethane intravaginal rings for the sustained combined delivery of antiretroviral agents dapi-virine and tenofovir. Eur J Pharm Sci 2010;39:203-212.
50. Dezzutti CS, et al.: Reformulated tenofovir gel for use as a dual compartment microbicide. J Antimicrob Chemother 2012;67:2139-2142.
51. Witvrouw M, et al.: Susceptibility of HIV-2, SIV and SHIV to various anti-HIV-1 compounds: Implications for treatment and postexposure prophylaxis. Antivir Ther 2004;9:57-65.
52. Gupta KM, et al.: Polyurethane intravaginal ring for controlled delivery of dapivirine, a nonnucleoside reverse tran-scriptase inhibitor of HIV-1. J Pharm Sci 2008;97:4228-4239.
53. Nel A, et al.: Safety and pharmacokinetics of dapivirine delivery from matrix and reservoir intravaginal rings to HIV-negative women. J Acquir Immune Defic Syndr 2009; 51:416-423.
54. Nuttall JP, et al.: Concentrations of dapivirine in the rhesus macaque and rabbit following once daily intravaginal administration of a gel formulation of [14C]-dapivirine for 7 days. Antimicrob Agents Chemother 2008;52:909-914.
55. Nel AM, et al.: Pharmacokinetic assessment of dapivirine vaginal microbicide gel in healthy, HIV-negative women. AIDS Res Hum Retroviruses 2010;26:1181-1190.
56. Nel AM, et al.: Safety, tolerability, and systemic absorption of dapivirine vaginal microbicide gel in healthy, HIVnegative women. AIDS 2009;23:1531-1538.
57. Nel AM, et al.: Pharmacokinetics of 2 dapivirine vaginal microbicide gels and their safety vs. hydroxyethyl cellulose-based universal placebo gel. J Acquir Immune Defic Syndr 2010;55:161-169.
58. Di Fabio S, et al.: Inhibition of vaginal transmission of HIV-1 in hu-SCID mice by the non-nucleoside reverse transcriptase inhibitor TMC120 in a gel formulation. AIDS 2003;17:1597-1604.